BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
2 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
3 Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, Yazici S, Ucisik AC, Vahaboglu MH. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. Medeni Med J 2021;36:201-8. [PMID: 34915677 DOI: 10.5222/MMJ.2021.52959] [Reference Citation Analysis]
4 Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
6 Zhang H, Chen F, Giang E, Bao F, Lauer GM, Marsh C, Law M, Pockros PJ. Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy. Antiviral Therapy 2021;26:3-8. [DOI: 10.1177/13596535211042205] [Reference Citation Analysis]
7 Choi HSJ, Sonneveld MJ, Farag MS, Brouwer WP, Brakenhoff SM, Hirode G, Gehring AJ, de Man RA, Hansen BE, Janssen HLA. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. J Viral Hepat 2021;28:1729-37. [PMID: 34514678 DOI: 10.1111/jvh.13613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Hsu YC, Wu JL, Tseng CH, Nguyen MH, Lin CW, Hung CL. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00917-4. [PMID: 34464721 DOI: 10.1016/j.cgh.2021.08.037] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
11 Liu Y, Xue J, Liao W, Yan H, Liang X. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy. J Clin Gastroenterol 2020;54:e73-82. [PMID: 32604147 DOI: 10.1097/MCG.0000000000001376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
14 Francque S. Innovative liver research continues during the current pandemic. JHEP Rep 2020;2:100121. [PMID: 32501436 DOI: 10.1016/j.jhepr.2020.100121] [Reference Citation Analysis]
15 Liem KS, Gehring AJ, Feld JJ, Janssen HL. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
17 Gao X, Duan X, Cai H, Hu Y, Liu M, Kang K, Zhou M, Fu D, Yi W. Pregnancy Outcome of Women with Chronic Hepatitis B who Discontinued Antiviral Treatment before or in the Early Pregnancy. Int J Med Sci 2020;17:170-5. [PMID: 32038100 DOI: 10.7150/ijms.38410] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lee HW, Lui GC, Wong VW. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int 2020;40:549-57. [PMID: 31845462 DOI: 10.1111/liv.14330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206-13. [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 22.3] [Reference Citation Analysis]
20 Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen H, Vanwolleghem T. Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. Viruses 2019;11:E687. [PMID: 31357522 DOI: 10.3390/v11080687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Chen CH. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply. Aliment Pharmacol Ther 2019;49:1106-7. [PMID: 30920034 DOI: 10.1111/apt.15183] [Reference Citation Analysis]
22 Huang R, Yao R, Wu W, Wang J, Wu C. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients. Aliment Pharmacol Ther 2019;49:1105-6. [PMID: 30920033 DOI: 10.1111/apt.15150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Chi H, Peng J, Janssen HLA. Reply. Clin Gastroenterol Hepatol 2019;17:1001-2. [PMID: 30902226 DOI: 10.1016/j.cgh.2018.10.005] [Reference Citation Analysis]
24 Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen HLA, Vanwolleghem T. Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion. J Viral Hepat 2019;26:766-9. [PMID: 30801868 DOI: 10.1111/jvh.13084] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Zhang L, Zhang FK. Recent advances in assessment and treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 209-219 [DOI: 10.11569/wcjd.v27.i4.209] [Reference Citation Analysis]
26 Wong GL, Wong VW, Chan HL. Towards finite oral antiviral treatment for chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:260-2. [PMID: 30795959 DOI: 10.1016/S2468-1253(19)30045-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
28 Dusheiko G, Wang B. Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future. Gastroenterology 2019;156:548-51. [PMID: 30641057 DOI: 10.1053/j.gastro.2019.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107-115. [PMID: 30450681 DOI: 10.1111/apt.15058] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
30 Ingiliz P, Canbay A. Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients. Aliment Pharmacol Ther 2018;47:1551-2. [PMID: 29878428 DOI: 10.1111/apt.14649] [Reference Citation Analysis]
31 Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
32 Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]